Floating systems: A novel approach towards gastroretentive drug delivery systems

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 2, Issue SUPPL. 3, 2010, Pages 1-7

  Nasa, Praveen ^a   Mahant, Sheefali ^a   Sharma, Deepika ^a  

^a MAHARISHI MARKANDESHWAR DEEMED TO BE UNIVERSITY   (India)

Author keywords

Buoyancy capabilities; Floating tablet; Gastroretentive drug delivery systems

Indexed keywords

AMPICILLIN; ANTACID AGENT; ANTIANEMIC AGENT; ATENOLOL; BENSERAZIDE PLUS LEVODOPA; CAPTOPRIL; CHLORDIAZEPOXIDE; CIFRAN OD; CINNARIZINE; CIPROFLOXACIN; CLARITHROMYCIN; CONVIRON; DIAZEPAM; DICLOFENAC; DILTIAZEM; FAMOTIDINE; FLUOROURACIL; FUROSEMIDE; INDOMETACIN; LIDOCAINE; MICROSPHERE; MISOPROSTOL; NIFEDIPINE; NIMODIPINE; OMEPRAZOLE; PARACETAMOL; PIROXICAM; POLYMER; RAMIPRIL; THEOPHYLLINE; TOPALKAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

BULK DENSITY; DRUG ABSORPTION; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG GRANULE; DRUG RETENTION; FLOATING DRUG DELIVERY SYSTEM; GASTRIC EMPTYING TIME; GASTROINTESTINAL TRACT; GASTRORETENTIVE DRUG DELIVERY SYSTEM; HIGH DENSITY DRUG DELIVERY SYSTEM; HYDROCOLLOID; HYDROGEL; LOW DENSITY DRUG DELIVERY SYSTEM; MAGNETISM; MOLECULAR WEIGHT; NONHUMAN; REVIEW; STOMACH CONTENT; SUSTAINED DRUG RELEASE; TABLET; TABLET COMPRESSION; TABLET FRIABILITY; TABLET HARDNESS;

EID: 77957607682     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Agyilirah GA, Green M, Ducret R. Evaluation of the gastric retention properties of a cross linked polymer coated tablet versus those of a non-disintegrating tablets. Int J Pharm 1991; 75: 241-247.
2. Hoffman F, Pressman JH, Code CF. Controlled entry of orally administered drugs, physiological considerations. Drug Dev Ind. Pharm 1983; 9: 1077-1085.
3. Deshpande AA, Shah NH, Rhodes CT, Malick W. Development of a novel controlled release system for gastric retention. Pharm. Res. 1997; 14: 815-819.
4. Kawashima Y, Niwa T, Takcuchi H, Hino T, Itoh Y. Hollow microspheres for use as a floating controlled drug delivery system in the stomach. J. Pharm. Sci. 1992; 81(2): 135-140.
5. Ichikawa M, Watemblc S, Miyake VA. Multiple unit oral floating dosage systems I: Preparation and in-vivo evaluation of floating and sustained release characteristics. J.Pharm.1991; Sci.80: l062-1066.
6. Sato Y, Kawashima Y, Takenchi H. "Invitro and in vivo evaluation of riboflavin containing microoballoons for floating controlled delivery system in healthy humans." Int. J.Pharm.2004; 275: 75-82.
7. Washington N, "Investigation into the barrier action of an alginate gastric reflux suppressant, Liquid Gaviscon", Drug Investig 1987; 2: 23-30.
8. Foldager J, Toftkjor H, "Antacid composition." US Patent 1991; 5068109.
9. Fabrcgas JL, Cucala CG, Pous J, Sites RA. In vitro testing of an antacid formulation with prolonged gastric residence time. Drug Dev. Ind. Pharm. 1994; 20: 1199-1212.
10. Ponchel G, Irache JM. Specific and nonspecific bioadhesive particulate system for oral delivery to the gastrointestinal tract. Adv. Drug Del. Rev. 1998; 34: 191-219.
11. Redniek AB, Tucker SJ. Sustained release bolus for animal husbandry.US Patent 1970; 3: 507,952.
12. Bechgaard H, Ladefoged K. Distribution of pellets in the gastrointestinal tract: The influence on transit time exerted by density or diameter of pellets. J. Pharm. Pharmacol.1978; 30: 690692.
13. Davis SS, Stockwell SF, Taylor MJ, Hardy JG, Whelley DR. The effect on density on the gastric emptying of single and multiple-unit dosage form. Pharm.Res.1986; 3: 208-213.
14. Hwang SJ, Park H. Gastric retentive drug delivery systems. Cri.Rev.Ther.Drug Carr. Syst.1998; 15: 234-284.
15. Ito R, Mchida Y, Sannan T, Nagai T. Magnetic granules: a novel system for specific drug delivery to oesophageal mucosa in oral administration. Int. J. Pharm.1990; 61: 109-117.
16. Fujimori J, Machida Y, Nagai T. Preparation of magnetically-responsive tablet and confirmation of its gastric residence in beagle dogs.STP Pharm.Sci.1994; 4: 425-430.
17. Griming R, Berntgen M. "Estimation of the gastric residence time magnetic dosage forms using the Heidlberg capsule." Pharmazie.1996; 51: 328-331.
18. Garg S, Sharma S. Gastroretentive Drug Delivery System. Business Briefing: Pharmatech.2003; 160-166.
19. Rubinstein A, Friend DR. Specific delivery to the gastrointestinal tract, in: Domb A.J (Ed.), Polymeric Site-Specific Pharmacotherapy, Wiley, Chichester 1994; 282-283.
20. Penners G, Lustig K, Jorg PVG. Expandable pharmaceutical forms.US patent 1997; 5: 651,985.
21. Jaimini M, Rana AC, Tanwar YS. Formulation and evaluation of famotidine floating tablets. Current Drug Delivery 2007; 4: 51-55.
22. Innuccelli V, Coppi G, Bernabei M T, Cameroni R. Air compartment multiple-unit system for prolonged gastric residence. Int. J. Pharm.1998; 174: 47-54.
23. Wu W, Zhou Q, Zhang HB, Ma GD, Fu CD. Studies on nimodipine sustained release tablet capable of floating on gastric fluids with prolonged gastric resident time. Yao Xue Bao.1997; 32: 786-790.
24. Ichikawa M, Watanabe S, Miyake Y. A new multiple unit oral floating dosage system. I: Preparation and in vitro evaluation of floating and sustained-release kinetics. Pharm Sci.1991; 80: 10621066.
25. Chen GL, Hao WH. In vitro performance of floating sustained release capsule of verapamil. Drug Dev. Ind. Pharm.1998; 24(11): 1067-1072.
26. Arora S, Ali J, Ahuja A, Khar KR, Baboota S. Floating Drug Delivery Systems: A Review. AAPS Pharm. Sci. Tech. 2005; 6 (3) Article 47.
27. Thanoo BC, Sunny MC, Jayakrishnan A. Oral sustained release drug delivery systems using polycarbonate microspheres capable of floating on the gastric fluids. J. Pharm. Pharmacol.1993; 45: 21-24.
28. Sheth PR, Tossounian JL. Sustained release pharmaceutical capsules.US patent1978; 4: 126,672.
29. Joseph NH, Laxmi S, Jayakrishnan A. A floating type oral dosage from for piroxicam based on hollow microspheres: in vitro and in vivo evaluation in rabbits. J.Cont. Rel. 2002; 79: 71-79.
30. Jorgen F, Toftkjor H. Antacid composition.US Patent 50681095.14: 815
31. Subrahmanyam CVS, Setty JT.Laboratory manual of physical pharmaceutics, Jain MK for vallabh prakashan 2002.
32. Shah SH, Patel JK, Patel NV. Stomach specific floating drug delivery system: A Review, Int. J. Pharm. Res. CODEN (USA): IJPRIF ISSN: 0974-4304.2009; 3: 623-633.
33. Pillay, Shinde AKJ. Gastroretentive Drug Delivery System: An 0verview.2008; 13: 543-548.
34. Koner P, Saudagar RB, Daharwal SJ. Gastro-Retentive Drugs: A Novel Approach Towards Floating Therapy, 2007; 5 (1): 2211-2215.
35. Seth SD.Text book of pharmacology, Reed Elsevier Ltd.2005
36. Rouge N, Allemann E, Gex-Fabry M. Comparative pharmacokinetic study of a floating multiple unit capsule, a high density multiple unit capsule and an immediate release tablet containing 25mg atenolol. Acta Pharm. Helv.1998; 73: 81-87 PubMed DOI: 10.1016/S0031-6865(97)00050-2.
37. Gupta SK. Stability studies of ampiciilin floating tablets (Ampiflot) and buffered Ampiflot [master's thesis].Jamaica NY: St John's University.1987.
38. Watanbe K, Machida Y, Takayama M, Iwta M, Nagai T. Preparation and evaluation of intragastric floating tablets having pH independent buoyancy and sustained release property. Arch. Pract. Pharm Yakuzaigaku.1993; 53: 1-7.
39. Talwar N, Sen H, Staniforth JN inventors. Orally administered controlled drug delivery system providing temporal and spatial control.US patent.2001; 6: 261 601.
40. Ozdemir N, Ordu S, Ozkan Y. Studies of floating dosage forms of furosemide: in vitro and in vivo evaluation of bilayer tablet formulation. Drug Dev. Ind. Pharm.2000; 26: 857-866. PubMed DOI: 10.1081/DDC-1001013096.
41. Phuapradit W. Influence of Tablet Buoyancy on Oral Absorption of Sustained Release Acetaminophen Matrix Tablets [dissertation]. [Thesis].Jamaica NY: St John's University.1989.
42. Wu W, Zhou Q, Zhang HB, Ma GD, Fu CD. Studies on nimodipine sustained release tablet capable of floating on gastric fluids with prolonged gastric resident time. Yao Xue Xue Bao.1997; 32: 786-790.
43. Gustafson JH, Weissman L, Weinfeld RE, Holazo AA, Khoo KC, Kalpan SA. Clinical bioavailability evaluation of a controlled release formulation of diazepam. J Pharm. Biopharm.1981; 9: 679-691.
44. Menon A, Ritschel WA, Sakr A. Development and evaluation of a monolithic floating dosage form for furosemide. J. Pharm. Sci.1994; 83: 239-245.
45. Khattar D, Ahuja A, Khar RK. Hydrodynamically balanced systems as sustained release dosage form for Propranalol hydrochloride.Pharmazine.1990; 45: 356-358.
46. Hilton AK, Deasy PB. In vitro and in vivo evaluation of an oral sustained Release floating dosage form of amoxicillin trihydrate. Int. J. Pharm.1992; 86: 79-88.
47. Malcolm SL, Allen JG, Bird H. Single dose pharmacokinetics of madopar HBS in volunteers. Eur. Neurol. 1987; 27: 28S-35S.
48. Inouye K, Machida Y, Sannan T, Nagai T.Buoyant sustained release tablets based on chitosan Drug delivery.1989; 4: 55-67.
49. Kawashima Y, Niwa T, Takcuchi H, Hino T, Itoh Y. Hollow microspheres for use as a floating controlled drug delivery system in the stomach. J. Pharm. Sci. 1992; 81(2): 135-140.
50. El-Kamel AH, Sokar MS, Gamal AA, Naggar V. Preparation and evaluation of ketoprofen floating oral drug delivery system. Int. J. Pharm.2001; 220: 13-21.
51. Kawashima Y, Niwa T, Takeuchi H, Hino T, Ito Y. Preparation of multiple unit hollow microspheres (microballoons) with acrylic resins containing tranilast and their drug release characteristics (in vivo). J. Control release.1991; 16: 279-290.
52. Jayanthi G, Jayaswal SB, Srivastava AK. Formulation and evaluation of terfenadine microballons for oral controlled release.Pharmazie.1995; 50: 769-770.Pubmed
53. Sungthongjeena S, Sriamornsak P, Puttipipatkhachorn S. Design and evaluation of floating multi-layer coated tablets based on gas formation. Eur. J. Pharm. and Biopharm.2008; 69: 255-263.
54. Rajnikanth P, Mishra B. Floating in situ gelling system for stomach site-specific delivery of clarithromycin to eradicate H.pylori. J. Cont. Rel.2008; 25: 33-41.